SLDB - Solid Biosciences LLC

SLDB - Solid Biosciences LLC

https://www.solidbio.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Solid Biosciences to Participate at Upcoming Investor Conferences - Solid Biosciences ( NASDAQ:SLDB )

Benzinga • 2 weeks, 4 days ago • score: 0.22

CHARLESTOWN, Mass., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. SLDB ( the "Company" or "Solid" ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Solid Biosciences ( NASDAQ:SLDB )

Benzinga • 1 month, 2 weeks ago • score: 0.19

CHARLESTOWN, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. SLDB ( the "Company" ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted stock units ( "RSUs" ) to four newly hired ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 month, 2 weeks ago • score: 0.19

CHARLESTOWN, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. ( Nasdaq: SLDB ) ( the "Company" ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted stock units ( "RSUs" ) to four ...

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Gold Royalty ( AMEX:GROY ) , IonQ ( NYSE:IONQ )

Benzinga • 2 months, 4 weeks ago • score: 0.15

U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday. Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Solid Biosciences ( NASDAQ:SLDB )

Benzinga • 3 months, 1 week ago • score: 0.20

CHARLESTOWN, Mass., June 03, 2025 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. SLDB ( the "Company" ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units ( "RSUs" ) to two newly hired ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. The company is headquartered in Cambridge, Massachusetts.

52W High

$8.45

52W Low

$2.41

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

2.55

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.69

EV/Revenue (<3 favorable)

1.16

P/S (TTM) (<3 favorable)

3.65

P/B (<3 favorable)

1.66

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.52%

Institutions (25–75% balanced)

105.94%

Shares Outstanding

77,869,000

Float

37,620,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-96,431,000

EPS (TTM)

-2.79

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.68%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

-0.1774

Previous

-0.1716

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025